An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors-Reference-Cited by-同舟云学术

An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors

Published:2022-04-13 Issue:8 Volume:117 Page:1279-1287
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:Am J Gastroenterol

Author:

Onali Sara,Pugliese Daniela,Caprioli Flavio Andrea,Orlando Ambrogio,Biancone Livia,Nardone Olga Maria,Imperatore Nicola,Fiorino Gionata,Cappello Maria,Viola Anna,Principi Maria Beatrice,Bezzio Cristina,Aratari Annalisa,Carparelli Sonia,Mazzuoli Silvia,Manguso Francesco,Grossi Laurino,Bodini Giorgia,Ribaldone Davide,Mocci Giammarco,Miranda Agnese,Minerba Luigi,Favale Agnese,Grova Mauro,Scucchi Ludovica,Segato Simone,Fries Walter,Castiglione Fabiana,Armuzzi Alessandro,Fantini Massimo C.,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference23 articles.

1. Crohn's disease;Torres;Lancet,2017

2. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining therapeutic goals for treat-to-target;Peyrin-Biroulet;Am J Gastroenterol,2015

3. STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD;Turner;Gastroenterology,2021

4. ECCO guidelines on therapeutics in Crohn's disease: Medical treatment;Torres;J Crohns Colitis,2020

5. Loss of response and need for adalimumab dose intensification in Crohn's disease: A systematic review;Billioud;Am J Gastroenterol,2011

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent clinical evidence on nutrition, novel pharmacotherapy, and vaccination in inflammatory bowel diseases;Frontiers in Pharmacology;2024-09-06

2. How comparative studies can inform treatment decisions for Crohn’s disease;Expert Opinion on Biological Therapy;2024-08-12

3. IBD Patients with Primary or Secondary Nonresponse to Ustekinumab Benefit from Dose Escalation or Reinduction;Journal of Clinical Medicine;2024-07-09

4. Factors Associated with Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel Disease;Digestive Diseases and Sciences;2024-07-04

5. Vedolizumab versus ustekinumab in Crohn’s disease with prior anti-tumor necrosis factor failure: an updated meta-analysis;European Journal of Gastroenterology & Hepatology;2024-07-02